131179-77-6

Basic information

• Product Name: N-(3,5-DIMETHYLPHENYL)-2-(4-HYDROXYPHENYL)ACETAMIDE
• Synonyms: N-(3,5-DIMETHYLPHENYL)-2-(4-HYDROXYPHENYL)ACETAMIDE;N-(3,5-DiMethylphenyl)-4-hydroxy-benzeneacetaMide
• CAS NO: 131179-77-6
• Molecular Formula: C₁₆H₁₇NO₂
• Molecular Weight: 255.31
• Product Categories: Aromatics;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 131179-77-6.mol

Chemical Properties

• Melting Point: 173-176°C
• Boiling Point: 483.7°Cat760mmHg
• Flash Point: 246.3°C
• Appearance: /
• Density: 1.191g/cm³
• Vapor Pressure: 5.57E-10mmHg at 25°C
• Refractive Index: 1.633
• Storage Temp.: Refrigerator
• Solubility: DMSO (Slightly), Methanol (Slightly)
• CAS DataBase Reference: N-(3,5-DIMETHYLPHENYL)-2-(4-HYDROXYPHENYL)ACETAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: N-(3,5-DIMETHYLPHENYL)-2-(4-HYDROXYPHENYL)ACETAMIDE(131179-77-6)
• EPA Substance Registry System: N-(3,5-DIMETHYLPHENYL)-2-(4-HYDROXYPHENYL)ACETAMIDE(131179-77-6)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 131179-77-6(Hazardous Substances Data)

Usage

Chemical Properties

Off-White Solid

Uses

Efaproxiral intermediate.

InChI:InChI=1/C16H17NO2/c1-11-7-12(2)9-14(8-11)17-16(19)10-13-3-5-15(18)6-4-13/h3-9,18H,10H2,1-2H3,(H,17,19)

Upstream product

• 156-38-7 4-hydroxyphenylacetate 
• 37859-23-7 2-(p-hydroxyphenyl)acetyl chloride 
• 108-69-0 3,5-dimethylaminoaniline 

Downstream Products

• 328236-03-9 (S)-6-Benzyloxycarbonylamino-2-[(1-{4-[(3,5-dimethyl-phenylcarbamoyl)-methyl]-phenoxy}-cyclopentanecarbonyl)-amino]-hexanoic acid methyl ester 
• 328236-09-5 2-[(1-{4-[(3,5-dimethyl-phenylcarbamoyl)-methyl]-phenoxy}-cyclopentanecarbonyl)-amino]-succinic acid 4-tert-butyl ester 1-methyl ester 
• 328236-08-4 (2S,3R)-2-[(1-{4-[(3,5-Dimethyl-phenylcarbamoyl)-methyl]-phenoxy}-cyclopentanecarbonyl)-amino]-3-hydroxy-butyric acid methyl ester 
• 328236-06-2 (S)-1-(1-{4-[(3,5-Dimethyl-phenylcarbamoyl)-methyl]-phenoxy}-cyclopentanecarbonyl)-pyrrolidine-2-carboxylic acid methyl ester 
• 328235-99-0 (S)-2-[(1-{4-[(3,5-Dimethyl-phenylcarbamoyl)-methyl]-phenoxy}-cyclopentanecarbonyl)-amino]-4-methylsulfanyl-butyric acid methyl ester 
• 328235-98-9 (R)-2-[(1-{4-[(3,5-Dimethyl-phenylcarbamoyl)-methyl]-phenoxy}-cyclopentanecarbonyl)-amino]-4-methylsulfanyl-butyric acid methyl ester 
• 328236-04-0 (2S,3S)-2-[(1-{4-[(3,5-Dimethyl-phenylcarbamoyl)-methyl]-phenoxy}-cyclopentanecarbonyl)-amino]-3-methyl-pentanoic acid methyl ester 
• 328236-01-7 (S)-2-[(1-{4-[(3,5-Dimethyl-phenylcarbamoyl)-methyl]-phenoxy}-cyclopentanecarbonyl)-amino]-3-hydroxy-propionic acid methyl ester 
• 328236-00-6 (R)-2-[(1-{4-[(3,5-Dimethyl-phenylcarbamoyl)-methyl]-phenoxy}-cyclopentanecarbonyl)-amino]-3-hydroxy-propionic acid methyl ester 

Relevant articles and documents

Mass spectrometric characterization of efaproxiral (RSR13) and its implementation into doping controls using liquid chromatography-atmospheric pressure ionization-tandem mass spectrometry

Efaproxiral (2-[4-[[(3,5-dimethylanilino)carbonyl]methyl]phenoxyl]-2- methylpropionic acid, formerly referred to as RSR13) is prohibited in sports according to the World Anti-Doping Agency (WADA). The drug as well as structurally related compounds and a stable isotope-labeled derivative have been synthesized to elucidate the fragmentation pathway of efaproxiral, using electrospray ionization (ESI) and tandem mass spectrometry by employing a novel linear ion trap - orbitrap hybrid mass spectrometer - in positive and negative ionization modes. The elimination of 2-methyl acrylic acid (-86 u) has been identified as a major fragmentation process in both charge states. Negative ionization and collision-induced dissociation (CID) caused an additional release of carbon dioxide (-44 u), and positive ionization the loss of formic acid (-46 u). Efaproxiral was incorporated into an existing screening procedure for doping controls using solid-phase extraction (SPE) followed by liquid chromatography-tandem mass spectrometry, enabling a limit of detection of 2.5 ng/ml and interday precisions ranging from 7.9 to 13.0%. Copyright

Insights into Fast Amide Couplings in Aqueous Nanomicelles

1-Ethyl-3-(3-(dimethylamino)propyl)-carbodiimide (EDC?HCl) has both lipophilic and hydrophilic regions, causing self-aggregation (also called nanoparticle formation) in an aqueous medium containing PS-750-M amphiphile. Kinetic and proton nuclear magnetic resonance studies were used to probe the effect of different organic bases on the potential nanoparticle formation of EDC?HCl. It also reveals why the pyridine base works better under micellar conditions. The methodology was examined on the multigram scale synthesis of bioactive molecules, where excellent reaction yields were obtained without product epimerization while maintaining a shorter reaction time.

Selective phenol alkylation: An improved preparation of efaproxiral

An improved, two-step synthesis of efaproxiral, used in breast cancer therapy, is described, utilizing inexpensive commodity chemicals for starting materials. Selective amide formation and O-alkylation in the presence of multireactive functional groups is demonstrated, thus avoiding protection/deprotection steps. Copyright Taylor & Francis Group, LLC.

Fast Amide Couplings in Water: Extraction, Column Chromatography, and Crystallization Not Required

In the micelle of PS-750-M, the presence of 3° amides from the surfactant proline linker mimics dimethylformamide, dimethylacetamide, and N-methyl-2-pyrrolidone. The resultant micellar properties enable extremely fast amide couplings mediated by 1-ethyl-3

Clickable coupling of carboxylic acids and amines at room temperature mediated by SO2F2: A significant breakthrough for the construction of amides and peptide linkages

The construction of amide bonds and peptide linkages is one of the most fundamental transformations in all life processes and organic synthesis. The synthesis of structurally ubiquitous amide motifs is essential in the assembly of numerous important molecules such as peptides, proteins, alkaloids, pharmaceutical agents, polymers, ligands and agrochemicals. A method of SO2F2-mediated direct clickable coupling of carboxylic acids with amines was developed for the synthesis of a broad scope of amides in a simple, mild, highly efficient, robust and practical manner (>110 examples, >90% yields in most cases). The direct click reactions of acids and amines on a gram scale are also demonstrated using an extremely easy work-up and purification process of washing with 1 M aqueous HCl to provide the desired amides in greater than 99% purity and excellent yields.

MCF-supported boronic acids as efficient catalysts for direct amide condensation of carboxylic acids and amines

For efficient direct amide condensations, a new class of catalysts are developed by immobilizing boronic acids on mesocellular siliceous foam. Associated with their large pores, the microenvironments surrounding the immobilized active species greatly influence the catalytic activity. The fluoroalkyl moieties on the silica surface significantly enhance the catalytic performance along with easy recovery and reuse. This approach proposes a potential way to optimize various types of silica-supported catalysts. the Partner Organisations 2014.

Compositions of allosteric hemoglobin modifiers and methods of making the same

The present invention provides novel compositions of allosteric hemoglobin modifiers which are substantially free of impurities, specifically polymeric impurities. In one embodiment, the novel compositions contain an allosteric hemoglobin modifier compoun

Substituted chiral allosteric hemoglobin modifiers

A family of substituted chiral allosteric effectors of hemoglobin is useful for delivering more oxygen to hypoxic and ischemic tissues by reducing the oxygen affinity of hemoglobin in whole blood.

Synthesis and structure - Activity relationships of chiral allosteric modifiers of hemoglobin

A series of allosteric effectors of hemoglobin, 2-(aryloxy)-2-alkanoic acids, was prepared to investigate the effect of the stereocenter on allosteric activity. The chiral analogues were based on the lead compound, RSR13 (3b), with different alkyl/alkanoic and cycloalkyl/cycloalkanoic groups positioned at the acidic chiral center. Of the 23 racemic molecules synthesized, 5 were selected for resolution based on structure - activity relationships. One chiral analogue, (-)-(1R,2R)-1-[4-[[(3,5-dimethylanilino)carbonyl]methyl]phenoxy]-2-methylcycl opentanecarboxylic acid (11), exhibited greater in vitro activity in hemoglobin solutions than its antipode, racemate, and RSR13. Compound (-)-(1R,2R)-11 was equipotent with RSR13 in whole blood, is a candidate for in vivo animal studies, and if efficacious and safe has a potential for use in humans. In general, it was found that chirality affects allosteric effector activity with measurable differences observed between enantiomers and the racemates.

Allosteric Modifiers of Hemoglobin. 1. Design, Synthesis, Testing, and Structure-Allosteric Activity Relationship of Novel Hemoglobin Oxygen Affinity Decreasing Agents

Three isomeric series of 2-(aryloxy)-2-methylpropionic acids were prepared and studied for their ability to decrease the oxygen affinity of human hemoglobin A.The isomeric aryloxy groups included 4-methyl>phenoxy, 4-(arylacetamido)phenoxy, and 4-methyl>phenoxy.A total of 20 compounds were synthesized and tested.Structure-activity relationships are presented.Several of the new compounds were found to be strong allosteric effectors of hemoglobin.The two most active compounds are 2-methyl>phenoxy>-2-methylpropionic acid and the corresponding 3,5-dimethyl derivative.The latter two compounds have been compared to other known potent allosteric effectors in the same assay and show greater activity.Both compounds also exhibit a right shift in the oxygen equilibrium curve when incubated with whole blood.The new compounds may be of interest in clinical or biological areas that require or would benefit from a reversal of depleted oxygen supply (i.e., ischemia, stroke, tumor radiotherapy, blood storage, blood substitutes, etc.).They are also structurally related to several marketed antilipidemic agents.